Ampicillin/Sulbactam: Current Status in Severe Bacterial Infections

Authors: Rafailidis, Petros I.; Ioannidou, Eleni N.¹; Falagas, Matthew E.

Source: Drugs, Volume 67, Number 13, 2007 , pp. 1829-1849(21)

Publisher: Adis International

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Ampicillin/sulbactam is a β-lactam/β-lactamase inhibitor combination with a broad spectrum of antibacterial activity against Gram-positive, Gram-negative and anaerobic bacteria. Data from comparative studies justify the use of ampicillin/sulbactam in a 2 : 1 ratio in various severe bacterial infections. In comparative clinical trials, ampicillin/sulbactam has proved to be a significant drug in the therapeutic armamentarium for lower respiratory tract infections and aspiration pneumonia, gynaecological/obstetrical infections, intra-abdominal infections, paediatric infections such as acute epiglottitis and periorbital cellulitis, diabetic foot infections, and skin and soft tissue infections. Of particular interest during this era of increasing antimicrobial resistance in various settings and populations is the effectiveness of sulbactam against a considerable proportion of infections due to Acinetobacter baumannii.

Keywords: Acinetobacter infections; Gynaecological infections; Intra abdominal infections; Paediatric infections; Pneumonia; Sepsis; Skin and soft tissue infections; Sulbactam/ampicillin

Document Type: Review article

Affiliations: 1: 1 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$68.55 plus tax